Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

Launched by NOVARTIS PHARMACEUTICALS · Mar 6, 2007

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and females 12 - 75 years of age
• • Fungal toenail infection of one or both of the large (great) toenails
• • The nail infection must be due to a dermatophyte, (mixed infections \[dermatophyte and non-dermatophyte\] are not allowed)
• Exclusion Criteria:
• • Target foot must not have severe plantar (moccasin) tinea pedis that would require systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be treated with terbinifine prior to baseline or at any time during the trial. Other topical treatments for athlete's foot may be recommended at the discretion of the investigator.
• • Subjects must not have abnormalities of the nail that could prevent a normal appearing nail if clearing of infection is achieved
• • No administration of systemic antifungal medications within 6 months prior to screening visit
• • No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit
• • No professional pedicures or application of any nail polish product or nail cosmetic to the toenails after the screening visit
• • Known pregnancy or lactation at time of enrollment
• • Other protocol-defined inclusion/exclusion criteria may apply